BridgeBio Pharma, Inc.
BBIO
$68.55
$2.603.94%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -721.55M | -724.93M | -797.12M | -776.42M | -667.97M |
| Total Depreciation and Amortization | 5.34M | 5.43M | 5.37M | 5.51M | 5.76M |
| Total Amortization of Deferred Charges | 7.79M | 7.59M | 8.20M | 9.09M | 9.09M |
| Total Other Non-Cash Items | 324.12M | 317.06M | 286.47M | 191.96M | 11.62M |
| Change in Net Operating Assets | -59.64M | -51.06M | -87.73M | -85.94M | 141.08M |
| Cash from Operations | -443.95M | -445.91M | -584.82M | -655.81M | -500.42M |
| Capital Expenditure | -1.17M | -1.10M | -1.11M | -778.00K | -238.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | 0.00 | -42.00K | -140.00K |
| Other Investing Activities | -64.46M | -23.39M | -12.26M | 21.21M | 36.81M |
| Cash from Investing | -65.63M | -24.49M | -13.37M | 20.39M | 36.43M |
| Total Debt Issued | 932.50M | 875.00M | 1.38B | 1.38B | 1.08B |
| Total Debt Repaid | 0.00 | -459.00M | -459.00M | -459.00M | -459.00M |
| Issuance of Common Stock | 56.45M | 34.15M | 23.79M | 17.92M | 10.76M |
| Repurchase of Common Stock | -99.02M | -62.50M | -56.48M | -54.89M | -54.90M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -41.07M | -28.35M | -47.90M | -42.01M | -42.62M |
| Cash from Financing | 848.86M | 359.29M | 835.41M | 837.01M | 529.24M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 339.28M | -111.10M | 237.22M | 201.59M | 65.25M |